# US 2026/0077097 A1 · Medical device that includes a rhenium-chromium alloy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077097 A1
- Document ID: US20260077097A1
- Status: Published application
- Kind: A1
- Application number: 19/401,465
- Filed: 2025-11-26
- Published: 2026-03-19
- Earliest claimed: 2022-03-03
- Assignees: MiRus LLC
- Applicants: MiRus LLC
- Inventors: Noah Roth
- Web page: https://patentgrep.com/patent/US20260077097A1

## CPC

- A61L 27/047: {Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06}
- A61F 2/2418: {Scaffolds therefor, e.g. support stents}
- A61F 2/90: characterised by a net-like or mesh-like structure
- A61L 27/06: Titanium or titanium alloys
- A61L 27/34: Macromolecular materials
- A61L 27/507: {for artificial blood vessels (apparatus for applying cells on a blood vessel prosthesis A61F2/062)}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 31/022: {Metals or alloys}
- A61L 31/088: {Other specific inorganic materials not covered by A61L31/084 or A61L31/086}
- A61L 31/10: Macromolecular materials
- A61L 31/14: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61L 31/18: Materials at least partially X-ray or laser opaque
- C22C 27/00: Alloys based on rhenium or a refractory metal not mentioned in groups C22C14/00 or C22C16/00
- C22C 27/06: Alloys based on chromium
- C22C 30/00: Alloys containing less than 50% by weight of each constituent
- A61F 2240/001: Designing or manufacturing processes
- A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/62: Encapsulated active agents, e.g. emulsified droplets
- A61L 2430/20: for reconstruction of the heart, e.g. heart valves
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- C22C: ALLOYS (treatment of alloys C21D, C22F)

## Abstract

A rhenium-chromium metal alloy or rhenium alloy that can be used to at least partially form a medical device.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A medical device that is partially or fully formed of a rhenium-chromium metal alloy; said rhenium-chromium metal alloy comprising rhenium and chromium; and wherein A) a weight percent of said rhenium in said rhenium-chromium metal alloy is at least 50 wt. %; a weight percent of said chromium in said rhenium-chromium metal alloy is at least 25 wt. %; a weight percent of alloying agent in said rhenium-chromium metal alloy is 0-25 wt. %; a combined weight percent of said rhenium and said chromium is at least 75 wt. % of said rhenium-chromium metal alloy; a weight percent of said rhenium in said rhenium-chromium metal alloy is greater than a weight percent of said chromium in said rhenium-chromium metal alloy; said alloying agent including one or more metals selected from a group consisting of molybdenum, bismuth, niobium, tantalum, titanium, vanadium, tungsten, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, yttrium, zirconium, and iridium, or B) a weight percent of said rhenium in said rhenium-chromium metal alloy is less than 50 wt. %; said rhenium-chromium metal alloy includes 0.1-50 wt. % alloying agent; said alloying agent including one or more metals selected from a group consisting of molybdenum, bismuth, niobium, tantalum, titanium, vanadium, tungsten, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, yttrium, zirconium, and iridium; a weight percent of said chromium in said rhenium-chromium metal alloy is at least 25 wt. %; a combined weight percent of said rhenium and said chromium is at least 50 wt. % of said rhenium-chromium metal alloy.

### Claim 24 (depends on 23)

The medical device as defined in claim 23, wherein said weight percent of rhenium in said rhenium-chromium metal alloy is at least 60 wt. % and said weight percent of said chromium in said rhenium-chromium metal alloy is at least 30 wt. %.

### Claim 25 (depends on 23)

The medical device as defined in claim 23, wherein said weight percent of rhenium in said rhenium-chromium metal alloy is at least 64 wt. % and said weight percent of said chromium in said rhenium-chromium metal alloy is at least 32.5 wt. %.

### Claim 26 (depends on 23)

The medical device as defined in claim 23, wherein said alloying agent constitutes 0.1-25 wt. % of said rhenium-chromium metal alloy; said alloying agent including one or more metals selected from a group consisting of molybdenum, bismuth, niobium, tantalum, titanium, vanadium, tungsten, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, yttrium, zirconium, and iridium.

### Claim 27 (depends on 26)

The medical device as defined in claim 26, wherein said alloying agent constitutes 0.1-5 wt. % of said rhenium-chromium metal alloy.

### Claim 28 (depends on 23)

The medical device as defined in claim 23, wherein said rhenium-chromium metal alloy includes 0-0.1 wt. % impurities.

### Claim 29 (depends on 23)

The medical device as defined in claim 23, wherein said rhenium-chromium metal alloy has a controlled amount of nitrogen, oxygen, and carbon to reduce micro-cracking in said rhenium-chromium metal alloy, a nitrogen content in said rhenium-chromium metal alloy is less than a combined content of oxygen and carbon in said rhenium-chromium metal alloy, said rhenium-chromium metal alloy has an oxygen to nitrogen atomic ratio of at least about 1.2:1, said rhenium-chromium metal alloy has a carbon to nitrogen atomic ratio of at least about 2:1.

### Claim 30 (depends on 23)

The medical device as defined in claim 23, wherein said medical device includes an expandable frame formed at least partially of said rhenium-chromium metal alloy; said expandable frame including a plurality of struts; said expandable frame is configured to be crimped to a crimped state such that a maximum outer diameter of said expandable frame when in said crimped state is less than a maximum outer diameter of said expandable frame when fully expanded to an expanded state.

### Claim 31 (depends on 30)

The medical device as defined in claim 30, wherein said expandable frame has a recoil of a) less than 5% after being subjected to a first crimping process; and/or b) less than 5% after being expanded from said crimped state to said expanded state.

### Claim 32 (depends on 23)

The medical device as defined in claim 23, wherein said rhenium-chromium metal alloy on said medical device has a hydrophilicity wherein a contact angle of a water droplet on a surface of said rhenium-chromium metal alloy of 25-45°.

### Claim 33 (depends on 23)

The medical device as defined in claim 23, wherein said rhenium-chromium metal alloy on said medical device has a maximum ion release of a primary component of said rhenium-chromium metal alloy when inserted or implanted on or in the body of the patient of no more than 0.5 μg/cm2 per day, wherein said primary component constitutes at least 2 wt. % of said rhenium-chromium metal alloy.

### Claim 34 (depends on 23)

The medical device as defined in claim 23, wherein said rhenium-chromium metal alloy on said medical device has an absolute increase in ion release per dose of rhenium-chromium metal alloy in tissue about said medical device of no more than 50 days after inserted or implanted on or in the body of a patient.

### Claim 35 (depends on 23)

The medical device as defined in claim 23, wherein said medical device is an expandable stent or an expandable prosthetic heart valve.

### Claim 36

A medical device that is partially or fully formed of a rhenium-chromium metal alloy; said rhenium-chromium metal alloy comprising rhenium and chromium; and wherein a weight percent of said rhenium in said rhenium-chromium metal alloy is at least 50 wt. %; a weight percent of said chromium in said rhenium-chromium metal alloy is at least 25 wt. %; a weight percent of alloying agent in said rhenium-chromium metal alloy is 0-25 wt. %; a combined weight percent of said rhenium and said chromium is at least 75 wt. % of said rhenium-chromium metal alloy; said alloying agent including one or more metals selected from a group consisting of bismuth, niobium, tantalum, titanium, vanadium, tungsten, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, yttrium, zirconium, and iridium.

### Claim 37

A medical device that is partially or fully formed of a rhenium-chromium metal alloy; said rhenium-chromium metal alloy comprising rhenium and chromium formed from a sintering process and an isostatic pressing process; an average particle size of metal particles used to form said rhenium-chromium metal alloy is less than about 150 microns; said metal particles having a purity of at least 99%; said rhenium-chromium metal alloy comprises A) at least 50 wt. % of said rhenium; at least 25 wt. % of said chromium; 0-25 wt. % alloying agent; a combined weight percent of said rhenium and said chromium is at least 75 wt. % of said rhenium-chromium metal alloy; a weight percent of said rhenium in said rhenium-chromium metal alloy is greater than a weight percent of said chromium in said rhenium-chromium metal alloy; said alloying agent includes one or more metals selected from a group consisting of molybdenum, bismuth, niobium, tantalum, titanium, vanadium, tungsten, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, yttrium, zirconium, and iridium, or B) less than 50 wt. % of said rhenium; 0.1-50 wt. % alloying agent; said alloying agent includes one or more metals selected from a group consisting of molybdenum, bismuth, niobium, tantalum, titanium, vanadium, tungsten, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, yttrium, zirconium, and iridium; a weight percent of said chromium in said rhenium-chromium metal alloy is at least 25 wt. %; a combined weight percent of said rhenium and said chromium is at least 50 wt. % of said rhenium-chromium metal alloy.

### Claim 38 (depends on 37)

The medical device as defined in claim 37, wherein said rhenium-chromium metal alloy includes 50-75 wt. % rhenium, 25-50 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, manganese, molybdenum, niobium, tantalum, vanadium, titanium, tungsten, yttrium, and zirconium.

### Claim 39 (depends on 37)

The medical device as defined in claim 37, wherein said rhenium-chromium metal alloy includes 50-75 wt. % rhenium, 25-50 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium; and said metal alloy includes 0-0.1 wt. % of secondary materials; said secondary materials are selected from the group consisting of a) metals other than rhenium, bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium, b) carbon, c) oxygen and d) nitrogen.

### Claim 40 (depends on 37)

The medical device as defined in claim 37, wherein said rhenium-chromium metal alloy includes 55-75 wt. % rhenium, 25-45 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium; and said metal alloy includes 0-0.1 wt. % of secondary materials; said secondary materials are selected from the group consisting of a) metals other than rhenium, bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium, b) carbon, c) oxygen and d) nitrogen.

### Claim 41 (depends on 37)

The medical device as defined in claim 37, wherein said rhenium-chromium metal alloy includes 50-75 wt. % rhenium, 25-50 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, manganese, molybdenum, niobium, tantalum, vanadium, titanium, tungsten, yttrium, and zirconium.

### Claim 42 (depends on 37)

The medical device as defined in claim 37 wherein said rhenium-chromium metal alloy includes 50-75 wt. % rhenium, 25-50 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium; and said metal alloy includes 0-0.1 wt. % of secondary materials; said secondary materials are selected from the group consisting of a) metals other than rhenium, bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium, b) carbon, c) oxygen and d) nitrogen.

### Claim 43 (depends on 37)

The medical device as defined in claim 37 wherein said rhenium-chromium metal alloy includes 55-75 wt. % rhenium, 25-45 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium; and said metal alloy includes 0-0.1 wt. % of secondary materials; said secondary materials are selected from the group consisting of a) metals other than rhenium, bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium, b) carbon, c) oxygen and d) nitrogen.

### Claim 44

A medical device that is partially or fully formed of a rhenium-chromium metal alloy; said rhenium-chromium metal alloy comprising rhenium and chromium; said rhenium-chromium has a crystalline structure of body-centered cubic (BCC); said rhenium-chromium metal alloy incudes:
A) at least 50 wt. % of said rhenium; at least 25 wt. % of said chromium; 0-25 wt. % alloying agent; a combined weight percent of said rhenium and said chromium is at least 75 wt. % of said rhenium-chromium metal alloy; a weight percent of said rhenium in said rhenium-chromium metal alloy is greater than a weight percent of said chromium in said rhenium-chromium metal alloy; said alloying agent includes one or more metals selected from a group consisting of molybdenum, bismuth, niobium, tantalum, titanium, vanadium, tungsten, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, yttrium, zirconium, and iridium; or
B) less than 50 wt. % of said rhenium; 0.1-50 wt. % alloying agent; said alloying agent includes one or more metals selected from a group consisting of molybdenum, bismuth, niobium, tantalum, titanium, vanadium, tungsten, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, yttrium, zirconium, and iridium; a weight percent of said chromium in said rhenium-chromium metal alloy is at least 25 wt. %; a combined weight percent of said rhenium and said chromium is at least 50 wt. % of said rhenium-chromium metal alloy; or
C) 50-75 wt. % rhenium, 25-50 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, manganese, molybdenum, niobium, tantalum, vanadium, titanium, tungsten, yttrium, and zirconium; or
D) 50-75 wt. % rhenium, 25-50 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium; and said metal alloy includes 0-0.1 wt. % of secondary materials; said secondary materials are selected from the group consisting of a) metals other than rhenium, bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium, b) carbon, c) oxygen and d) nitrogen; or
E) 55-75 wt. % rhenium, 25-45 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium; and said metal alloy includes 0-0.1 wt. % of secondary materials; said secondary materials are selected from the group consisting of a) metals other than rhenium, bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium, b) carbon, c) oxygen and d) nitrogen; or
F) 50-75 wt. % rhenium, 25-50 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, manganese, molybdenum, niobium, tantalum, vanadium, titanium, tungsten, yttrium, and zirconium; or
G) 50-75 wt. % rhenium, 25-50 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium; and said metal alloy includes 0-0.1 wt. % of secondary materials; said secondary materials are selected from the group consisting of a) metals other than rhenium, bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium, b) carbon, c) oxygen and d) nitrogen; or
H) 55-75 wt. % rhenium, 25-45 wt. % Cr, and 0.5-25 wt. % of said alloying agent; said alloying agent includes one or more metals selected from the group consisting of bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium; and said metal alloy includes 0-0.1 wt. % of secondary materials; said secondary materials are selected from the group consisting of a) metals other than rhenium, bismuth, iridium, molybdenum, niobium, tantalum, vanadium, yttrium, and zirconium, b) carbon, c) oxygen and d) nitrogen; or
I) 0.5-60 atomic weight percent (atw. %) Re and 0.5-70 awt. % chromium; and one or more of molybdenum, tantalum, niobium, titanium and zirconium; a combined atomic weight percent of rhenium and chromium is at least 60 awt. %.

### Claim 45 (depends on 44)

The medical device as defined in claim 44 wherein an outer surface of said medical device includes a nitride layer.

### Claim 46 (depends on 44)

The medical device as defined in claim 44 wherein said medical device is a rod, tube, expandable stent, expandable frame or hypotube.

### Claim 47 (depends on 46)

The medical device as defined in claim 46 wherein said medical device is said expandable stent or said expandable frame; said component includes a plurality of struts; said component is configured to be crimped to a crimped state such that a maximum outer diameter of said component when in said crimped state is less than a maximum outer diameter of said component when fully expanded to an expanded state.

### Claim 48 (depends on 47)

The medical device as defined in claim 47 wherein said medical device has a recoil of a) less than 5% after being subjected to a first crimping process; and/or b) less than 5% after being expanded from said crimped state to said expanded state.

### Claim 49 (depends on 47)

The medical device as defined in claim 47 wherein said medical device has a recoil of a) less than 5% after being subjected to a first crimping process; b) less than 5% after being expanded from said crimped state to said expanded state; c) has a hydrophilicity wherein a contact angle of a water droplet on a surface of said rhenium-chromium metal alloy of 25-45°; and d) said rhenium-chromium metal alloy has a maximum ion release of a primary component of said rhenium-chromium metal alloy when inserted or implanted on or in the body of the patient of no more than 0.5 μg/cm2 per day, wherein said primary component constitutes at least 2 wt. % of said rhenium-chromium metal alloy; and e) said rhenium-chromium metal alloy has an absolute increase in ion release per dose of rhenium-chromium metal alloy in tissue about said rhenium-chromium metal alloy of no more than 50 days after inserted or implanted on or in the body of a patient.
